KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $5.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 27.78% year-over-year to $5.8 million, compared with a TTM value of $5.8 million through Sep 2025, down 27.78%, and an annual FY2024 reading of $5.7 million, down 30.45% over the prior year.
  • Non-Current Deffered Revenue was $5.8 million for Q3 2025 at AbCellera Biologics, down from $11.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $64.8 million in Q2 2022 and bottomed at $5.7 million in Q4 2024.
  • Average Non-Current Deffered Revenue over 5 years is $27.0 million, with a median of $19.5 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue soared 123.29% in 2022, then plummeted 73.66% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $27.4 million in 2021, then decreased by 28.8% to $19.5 million in 2022, then tumbled by 58.01% to $8.2 million in 2023, then crashed by 30.45% to $5.7 million in 2024, then rose by 2.63% to $5.8 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ABCL at $5.8 million in Q3 2025, $11.6 million in Q2 2025, and $13.8 million in Q1 2025.